» Articles » PMID: 35955507

Exogenous ANP Treatment Ameliorates Myocardial Insulin Resistance and Protects Against Ischemia-Reperfusion Injury in Diet-Induced Obesity

Abstract

Increasing evidence suggests natriuretic peptides (NPs) coordinate interorgan metabolic crosstalk. We recently reported exogenous ANP treatment ameliorated systemic insulin resistance by inducing adipose tissue browning and attenuating hepatic steatosis in diet-induced obesity (DIO). We herein investigated whether ANP treatment also ameliorates myocardial insulin resistance, leading to cardioprotection during ischemia-reperfusion injury (IRI) in DIO. Mice fed a high-fat diet (HFD) or normal-fat diet for 13 weeks were treated with or without ANP infusion subcutaneously for another 3 weeks. Left ventricular BNP expression was substantially reduced in HFD hearts. Intraperitoneal-insulin-administration-induced Akt phosphorylation was impaired in HFD hearts, which was restored by ANP treatment, suggesting that ANP treatment ameliorated myocardial insulin resistance. After ischemia-reperfusion using the Langendorff model, HFD impaired cardiac functional recovery with a corresponding increased infarct size. However, ANP treatment improved functional recovery and reduced injury while restoring impaired IRI-induced Akt phosphorylation in HFD hearts. Myocardial ultrastructural analyses showed increased peri-mitochondrial lipid droplets with concomitantly decreased ATGL and HSL phosphorylation levels in ANP-treated HFD, suggesting that ANP protects mitochondria from lipid overload by trapping lipids. Accordingly, ANP treatment attenuated mitochondria cristae disruption after IRI in HFD hearts. In summary, exogenous ANP treatment ameliorates myocardial insulin resistance and protects against IRI associated with mitochondrial ultrastructure modifications in DIO. Replenishing biologically active NPs substantially affects HFD hearts in which endogenous NP production is impaired.

Citing Articles

ANP Increases Zn Accumulation During Reperfusion in Ex Vivo and In Vivo Hearts.

Ma Y, Laga T, Zhong C, Zhuang B, Quan H, Hong L Curr Med Sci. 2025; 45(1):35-50.

PMID: 40014195 DOI: 10.1007/s11596-025-00019-1.


Blunted increase in plasma BNP during acute coronary syndrome attacks in obese patients.

Okuyama T, Nagoshi T, Hiraki N, Tanaka T, Oi Y, Kimura H Int J Cardiol Heart Vasc. 2024; 54:101508.

PMID: 39314921 PMC: 11417597. DOI: 10.1016/j.ijcha.2024.101508.


Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients.

Kashiwagi Y, Nagoshi T, Tanaka Y, Oi Y, Kimura H, Ogawa K Sci Rep. 2024; 14(1):16493.

PMID: 39020009 PMC: 11255280. DOI: 10.1038/s41598-024-67524-6.


NPRC deletion attenuates cardiac fibrosis in diabetic mice by activating PKA/PKG and inhibiting TGF-β1/Smad pathways.

Meng L, Lu Y, Wang X, Cheng C, Xue F, Xie L Sci Adv. 2023; 9(31):eadd4222.

PMID: 37531438 PMC: 10396312. DOI: 10.1126/sciadv.add4222.


Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure.

Raffa S, Forte M, Gallo G, Ranieri D, Marchitti S, Magri D Cell Mol Life Sci. 2023; 80(5):134.

PMID: 37099206 PMC: 10133375. DOI: 10.1007/s00018-023-04777-w.


References
1.
Lopaschuk G, Karwi Q, Tian R, Wende A, Abel E . Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021; 128(10):1487-1513. PMC: 8136750. DOI: 10.1161/CIRCRESAHA.121.318241. View

2.
Barger P, Kelly D . PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2001; 10(6):238-45. DOI: 10.1016/s1050-1738(00)00077-3. View

3.
Bachmann K, Gupta D, Xu M, Brittain E, Farber-Eger E, Arora P . Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure. JACC Heart Fail. 2021; 9(3):192-200. PMC: 7914207. DOI: 10.1016/j.jchf.2020.10.008. View

4.
Wang T, Larson M, Levy D, Benjamin E, Leip E, Wilson P . Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109(5):594-600. DOI: 10.1161/01.CIR.0000112582.16683.EA. View

5.
Osumi T, Kuramoto K . Heart lipid droplets and lipid droplet-binding proteins: Biochemistry, physiology, and pathology. Exp Cell Res. 2015; 340(2):198-204. DOI: 10.1016/j.yexcr.2015.10.031. View